The full report is titled “Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.” It is in the 18 February 2014 issue of Annals of Internal Medicine (volume 160, pages 271-281). The author is V.A. Moyer, on behalf of the U.S. Preventive Services Task Force.
This article was published online first at www.annals.org on 24 December 2013.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Rebecca Mueller, Susan M. Domchek, Katherin L. Nathanson
University of Pennsylvania
January 9, 2014
Concerns regarding the USPSTF on BRCA testing
The recently released USPSTF statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women included important revisions from the draft statement released in April 2013, however it has several limitations. In particular, the exclusion of affected individuals (i.e. those with a personal history of cancer) is problematic. Although the statement notes that affected individuals may be the ideal candidate to undergo BRCA testing via screening of their unaffected relatives, it fails to recognize the preventive benefits associated with identification of genetic risk due to BRCA1/2 in individuals with a history of cancer. Women with a history of breast cancer not only “should be encouraged to discuss further evaluation with their clinician,” but should also have access to the screening and prevention for the second primary cancers that they are at significantly increased risk of developing. Primary providers may be helpful in identification of testing candidates who are no longer followed by oncology professionals. Secondary prevention strategies (particularly risk-reducing oophorectomy) significantly reduce cancer risk and mortality in this population.1 Additionally, this information allows family members to undergo single-site testing for the known mutation, or to avoid genetic testing if no mutation is identified in the affected individual, which is a more cost-effective and rational approach to testing within a family. In addition, the statement fails to recognize:1. That men may derive benefit from genetic testing for mutations in BRCA1/2. Male carriers have higher risks for male breast cancer, prostate cancer, melanoma, and pancreatic cancer. We believe it is inappropriate to exclude men as potential beneficiaries from mutation testing. 2. The challenges of testing women between ages 18-24. In general, specialized screening and prevention options are not initiated in female carriers until age 25.2 Knowing one is at high risk but not yet at the age to be screened should be part of the genetic counseling discussion for when to initiate testing. 3. That more comprehensive BRCA testing, beyond founder mutations, is sometimes indicated in individuals of Jewish ancestry.Finally, we feel that the statement “Evidence is lacking on the effect of intensive screening for BRCA-related cancer on clinical outcomes in women who are BRCA mutation carriers” may be misleading to primary providers. Although there are no randomized studies, there are data to suggest an improvement in stage of diagnosis with intensive breast cancer screening.3 Sincerely, Rebecca Mueller, MS, CGCGenetic Counselor, University of Pennsylvania MacDonald Cancer Risk Evaluation ProgramPhiladelphia, Pennsylvania Rebecca.email@example.comSusan Domchek, MDDirector, Basser Research Center for BRCA, University of Pennsylvania Director, MacDonald Cancer Risk Evaluation ProgramAbramson Cancer CenterPhiladelphia, Pennsylvania Susan.firstname.lastname@example.orgKatherine L. Nathanson, MDAssociate Professor of Medicine, University of Pennsylvania Co-Leader, Cancer Control ProgramChief Oncogenomics PhysicianAbramson Cancer CenterPhiladelphia, Pennsylvania Katherine.email@example.comOn behalf of the University of Pennsylvania MacDonald Cancer Risk Evaluation ProgramReferences: 1 Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 1;304(9):967-75.2 National Comprehensive Cancer Network [Internet]. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian- Version 4.2013 Hereditary Breast and/or Ovarian Cancer Syndrome, HBOC-A. Accessed online 1-6-2014. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf3 Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer. 2012 Jun 26;107(1):24-30.
Assessing the Genetic Risk for BRCA-Related Breast or Ovarian Cancer in Women: Recommendations From the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160:I–16. doi: https://doi.org/10.7326/P14-9008
Download citation file:
Published: Ann Intern Med. 2014;160(4):I-16.
Breast Cancer, Cancer Screening/Prevention, Hematology/Oncology, Prevention/Screening.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use